update - ניתוח השתלת מיאלין
סתם לעדכן אותכם. לפני כמה ימים נערך ניתוח שני מסוגו (הראשון היה לפני חודשים ספורים) בו (אם הבנתי נכון) השתילו לחולה טרפצת, בראש, מיאלין שנלקח ממערכת העצבים הפריפריאלית (יענו - לא המרכזית), בנסיון "לתקן" את המיאלין בראש. לפחות עושה רושם שעדיין "עובדים" על המחלה.... למי שמעונין - הנה תקציר: ("יישור" השורות הוא לצערי לצד ימין, אני לא יודעת לתקן את זה, אבל צריך לקרוא את זה משמאל לימין כמובן, עמכם הסליחה). Second patient with multiple sclerosis undergoes transplantation surgery at Yale A 29-year-old man with multiple sclerosis is the second patient to undergo transplantation surgery at Yale in an effort to repair myelin. The surgery took place in two stages on March 6-7 and the patient was discharged March 10. The young man is the second of five patients who are scheduled to participate in the groundbreaking clinical trial. There are an estimated 1.4 million persons worldwide with multiple sclerosis. The young man in the trial suffers from a relapsing form of multiple sclerosis. The third patient will be included in the trial next month. The purpose of the Phase One trial is to determine whether cells found in the body´s peripheral nerves, in this case, the ankle, can safely repair the damaged cells in the brain and spinal cord that result in neurologic disability in patients with multiple sclerosis and other disorders of myelin. In the first procedure on March 6, the surgical team harvested Schwann cells from the patient´s ankle. Animal studies show that Schwann cells can replace the oligodendrocytes. The second day, the cells were injected into the left posterior aspect of the patient´s brain, which has lesions. The aim of the trial is to determine whether the Schwann cells survive in the brain and if they are able to restore myelin on the nerve fibres in the brain. The patient´s progress is then monitored for six months using neuroimaging and other tests. After six months a small biopsy is taken to determine whether the cells survived and whether they made any myelin. The six month results on the first patient will not be made public until they are published in a peer-reviewed medical journal. לילה טוב, ענת
סתם לעדכן אותכם. לפני כמה ימים נערך ניתוח שני מסוגו (הראשון היה לפני חודשים ספורים) בו (אם הבנתי נכון) השתילו לחולה טרפצת, בראש, מיאלין שנלקח ממערכת העצבים הפריפריאלית (יענו - לא המרכזית), בנסיון "לתקן" את המיאלין בראש. לפחות עושה רושם שעדיין "עובדים" על המחלה.... למי שמעונין - הנה תקציר: ("יישור" השורות הוא לצערי לצד ימין, אני לא יודעת לתקן את זה, אבל צריך לקרוא את זה משמאל לימין כמובן, עמכם הסליחה). Second patient with multiple sclerosis undergoes transplantation surgery at Yale A 29-year-old man with multiple sclerosis is the second patient to undergo transplantation surgery at Yale in an effort to repair myelin. The surgery took place in two stages on March 6-7 and the patient was discharged March 10. The young man is the second of five patients who are scheduled to participate in the groundbreaking clinical trial. There are an estimated 1.4 million persons worldwide with multiple sclerosis. The young man in the trial suffers from a relapsing form of multiple sclerosis. The third patient will be included in the trial next month. The purpose of the Phase One trial is to determine whether cells found in the body´s peripheral nerves, in this case, the ankle, can safely repair the damaged cells in the brain and spinal cord that result in neurologic disability in patients with multiple sclerosis and other disorders of myelin. In the first procedure on March 6, the surgical team harvested Schwann cells from the patient´s ankle. Animal studies show that Schwann cells can replace the oligodendrocytes. The second day, the cells were injected into the left posterior aspect of the patient´s brain, which has lesions. The aim of the trial is to determine whether the Schwann cells survive in the brain and if they are able to restore myelin on the nerve fibres in the brain. The patient´s progress is then monitored for six months using neuroimaging and other tests. After six months a small biopsy is taken to determine whether the cells survived and whether they made any myelin. The six month results on the first patient will not be made public until they are published in a peer-reviewed medical journal. לילה טוב, ענת
